NRX Pharmaceuticals (STU:B1Q) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NRX Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

NRX Pharmaceuticals ROCE % Historical Data

The historical data trend for NRX Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals ROCE % Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-267.38

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial											-878.10	-	-	-	-

NRX Pharmaceuticals ROCE % Calculation

NRX Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-27.538	/	( ( (24.37 - 14.712)	+	(6.708 - 17.467) )	/ 2 )
	=	-27.538	/	( (9.658	+	-10.759)	/ 2 )
	=	-27.538	/	-0.5505
	=	5,002.36 %

NRX Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-23.176	/	( ( (6.708 - 17.467)	+	(3.485 - 17.348) )	/ 2 )
	=	-23.176	/	( ( -10.759	+	-13.863 )	/ 2 )
	=	-23.176	/	-12.311
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

NRX Pharmaceuticals (STU:B1Q) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NRX Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals (STU:B1Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NRXP:USA

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines